Algorae Pharmaceuticals Overview
- Year Founded
-
1987

- Status
-
Public
- Employees
-
48

- Stock Symbol
-
1AI

- Investments
-
2
Algorae Pharmaceuticals General Information
Description
Algorae Pharmaceuticals Ltd is a clinical-stage pharmaceutical company developing transformative solutions for under met medical needs in the community. The firm develops AlgoraeOS, a closed-loop platform, leveraging computational tools to generate novel insights in silico that are being developed to initiate or accelerate therapeutic programs. The products of the company comprise AI-116, a novel combination drug candidate of cannabidiol (CBD) and an off-patent pharmaceutical ingredient. The company is conceptualized to be a potential treatment for dementia, including Alzheimer's disease, NTCELL is an alginate-coated capsule containing clusters of neonatal porcine choroid plexus cells. It also offers LP-003 Anti-obesity Drug and LC-002 migraine treatment.
Contact Information
Website
www.algoraepharma.comCorporate Office
- Level 23, Rialto South Tower
- 525 Collins Street
- Melbourne, Victoria 3000
- Australia
Corporate Office
- Level 23, Rialto South Tower
- 525 Collins Street
- Melbourne, Victoria 3000
- Australia
Algorae Pharmaceuticals Timeline
Algorae Pharmaceuticals Stock Performance
As of 10-Feb-2025, Algorae Pharmaceuticals’s current market cap is $6.86M with 1.69B shares.
(As of Monday Closing)
Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
---|---|---|---|---|---|---|
$6.86M | 1.69B | 1.05M |
Algorae Pharmaceuticals Financials Summary
As of 31-Dec-2024, Algorae Pharmaceuticals has a trailing 12-month revenue of null.
In Thousands, USD |
TTM 31-Dec-2024 | FY 2024 30-Jun-2024 | FY 2023 30-Jun-2023 | FY 2022 30-Jun-2022 |
---|---|---|---|---|
EV | 4,218 | 8,754 | 12,769 | 4,158 |
EBITDA | (1,455) | (1,445) | (1,721) | |
Net Income | (1,373) | (1,417) | (1,418) | |
Total Assets | 2,134 | 2,788 | 2,940 | |
Total Debt | 0 | 0 | 0 |
Algorae Pharmaceuticals Valuation & Funding
Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
---|
Algorae Pharmaceuticals Comparisons
Industry
Financing
Details
Algorae Pharmaceuticals Competitors (3)
One of Algorae Pharmaceuticals’s 3 competitors is Orgenesis, a Corporation company based in Germantown, MD.
Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
---|---|---|---|---|---|---|
Orgenesis | Corporation | Germantown, MD | ||||
Agenus | Formerly VC-backed | Lexington, MA | ||||
Lineage Cell Therapeutics | Corporation | Carlsbad, CA |
Algorae Pharmaceuticals Patents
Algorae Pharmaceuticals Recent Patent Activity
Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
---|---|---|---|---|---|
AU-2007200990-B2 | Cell implantation to prevent and/or treat hearing loss | Inactive | 21-Nov-2006 | ||
US-20080119909-A1 | Cell implantation to prevent and/or treat hearing loss | Inactive | 21-Nov-2006 | ||
AU-2009202749-A1 | Cell implantation to prevent and/or treat hearing loss | Active | 21-Nov-2006 | ||
US-20150164990-A1 | Compositions and methods for preventing and/or treating sensorineural hearing loss | Inactive | 21-Nov-2006 | ||
AU-2009202749-B2 | Cell implantation to prevent and/or treat hearing loss | Inactive | 21-Nov-2006 | A61K35/30 |
Algorae Pharmaceuticals Signals
Algorae Pharmaceuticals Investors
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
---|
Algorae Pharmaceuticals Investments (2)
Algorae Pharmaceuticals’s most recent deal was a Joint Venture with Diatranz Otsuka. The deal was made on 01-Nov-2011.
Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
---|---|---|---|---|---|
Diatranz Otsuka | 01-Nov-2011 | Joint Venture | Drug Discovery | ||
CytoSolv | 09-Feb-2010 | Seed Round | Biotechnology |
Algorae Pharmaceuticals ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile

Pharmaceuticals
Industry
Rank
Percentile

Biotechnology
Subindustry
Rank
Percentile

Algorae Pharmaceuticals Exits (2)
Algorae Pharmaceuticals’s most recent exit was on 01-Nov-2011 from Diatranz Otsuka. The exit was categorized as with 2 buyers.
Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
---|---|---|---|---|---|
Diatranz Otsuka | 01-Nov-2011 | Completed |
|
||
CytoSolv | 09-Feb-2010 | Seed Round | Completed |
|
Algorae Pharmaceuticals FAQs
-
When was Algorae Pharmaceuticals founded?
Algorae Pharmaceuticals was founded in 1987.
-
Where is Algorae Pharmaceuticals headquartered?
Algorae Pharmaceuticals is headquartered in Melbourne, Australia.
-
What is the size of Algorae Pharmaceuticals?
Algorae Pharmaceuticals has 48 total employees.
-
What industry is Algorae Pharmaceuticals in?
Algorae Pharmaceuticals’s primary industry is Biotechnology.
-
Is Algorae Pharmaceuticals a private or public company?
Algorae Pharmaceuticals is a Public company.
-
What is Algorae Pharmaceuticals’s stock symbol?
The ticker symbol for Algorae Pharmaceuticals is 1AI.
-
What is the current market cap of Algorae Pharmaceuticals?
The current market capitalization of Algorae Pharmaceuticals is $6.86M.
-
Who are Algorae Pharmaceuticals’s competitors?
Orgenesis, Agenus, and Lineage Cell Therapeutics are competitors of Algorae Pharmaceuticals.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »